nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—OPRM1—nicotine dependence	0.811	1	CbGaD
Loperamide—POMC—cardiovascular system—nicotine dependence	0.00541	0.162	CbGeAlD
Loperamide—POMC—midbrain—nicotine dependence	0.00423	0.127	CbGeAlD
Loperamide—POMC—brain—nicotine dependence	0.00265	0.0796	CbGeAlD
Loperamide—CACNA1A—brain—nicotine dependence	0.00253	0.076	CbGeAlD
Loperamide—OPRM1—midbrain—nicotine dependence	0.00159	0.0477	CbGeAlD
Loperamide—Urinary retention—Varenicline—nicotine dependence	0.00151	0.0564	CcSEcCtD
Loperamide—CALM2—cardiovascular system—nicotine dependence	0.00148	0.0443	CbGeAlD
Loperamide—CALM1—cardiovascular system—nicotine dependence	0.00147	0.0441	CbGeAlD
Loperamide—CALM3—midbrain—nicotine dependence	0.00147	0.0441	CbGeAlD
Loperamide—OPRD1—brain—nicotine dependence	0.00147	0.0439	CbGeAlD
Loperamide—Abdominal pain upper—Varenicline—nicotine dependence	0.00145	0.0542	CcSEcCtD
Loperamide—OPRK1—brain—nicotine dependence	0.0014	0.0421	CbGeAlD
Loperamide—Abdominal distension—Varenicline—nicotine dependence	0.00138	0.0516	CcSEcCtD
Loperamide—Difenoxin—OPRM1—nicotine dependence	0.00131	0.141	CrCbGaD
Loperamide—Anileridine—OPRM1—nicotine dependence	0.00127	0.137	CrCbGaD
Loperamide—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00121	0.0453	CcSEcCtD
Loperamide—Levomethadyl Acetate—CHRNB4—nicotine dependence	0.00118	0.127	CrCbGaD
Loperamide—CALM2—midbrain—nicotine dependence	0.00115	0.0346	CbGeAlD
Loperamide—CALM1—midbrain—nicotine dependence	0.00115	0.0344	CbGeAlD
Loperamide—CYP2B6—cardiovascular system—nicotine dependence	0.0011	0.0329	CbGeAlD
Loperamide—Urinary tract disorder—Varenicline—nicotine dependence	0.00108	0.0405	CcSEcCtD
Loperamide—Urethral disorder—Varenicline—nicotine dependence	0.00107	0.0402	CcSEcCtD
Loperamide—Methadyl Acetate—OPRM1—nicotine dependence	0.00107	0.115	CrCbGaD
Loperamide—Erythema multiforme—Varenicline—nicotine dependence	0.00104	0.0388	CcSEcCtD
Loperamide—OPRM1—brain—nicotine dependence	0.000999	0.03	CbGeAlD
Loperamide—Immune system disorder—Varenicline—nicotine dependence	0.000989	0.0371	CcSEcCtD
Loperamide—Methadone—CHRNA10—nicotine dependence	0.00096	0.103	CrCbGaD
Loperamide—Flatulence—Varenicline—nicotine dependence	0.000939	0.0352	CcSEcCtD
Loperamide—CALM3—brain—nicotine dependence	0.000923	0.0277	CbGeAlD
Loperamide—Diphenoxylate—OPRM1—nicotine dependence	0.000921	0.0992	CrCbGaD
Loperamide—Angioedema—Varenicline—nicotine dependence	0.000871	0.0326	CcSEcCtD
Loperamide—Loss of consciousness—Varenicline—nicotine dependence	0.000838	0.0314	CcSEcCtD
Loperamide—Levomethadyl Acetate—CHRNA3—nicotine dependence	0.000816	0.0879	CrCbGaD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.000806	0.0302	CcSEcCtD
Loperamide—Discomfort—Varenicline—nicotine dependence	0.000802	0.03	CcSEcCtD
Loperamide—Dry mouth—Varenicline—nicotine dependence	0.000794	0.0297	CcSEcCtD
Loperamide—Nervous system disorder—Varenicline—nicotine dependence	0.000763	0.0286	CcSEcCtD
Loperamide—Skin disorder—Varenicline—nicotine dependence	0.000756	0.0283	CcSEcCtD
Loperamide—CALM2—brain—nicotine dependence	0.000725	0.0217	CbGeAlD
Loperamide—CALM1—brain—nicotine dependence	0.000722	0.0216	CbGeAlD
Loperamide—Somnolence—Varenicline—nicotine dependence	0.000692	0.0259	CcSEcCtD
Loperamide—Dyspepsia—Varenicline—nicotine dependence	0.000685	0.0257	CcSEcCtD
Loperamide—Gastrointestinal disorder—Varenicline—nicotine dependence	0.000672	0.0252	CcSEcCtD
Loperamide—Fatigue—Varenicline—nicotine dependence	0.000671	0.0251	CcSEcCtD
Loperamide—Constipation—Varenicline—nicotine dependence	0.000665	0.0249	CcSEcCtD
Loperamide—Gastrointestinal pain—Varenicline—nicotine dependence	0.000636	0.0238	CcSEcCtD
Loperamide—Urticaria—Varenicline—nicotine dependence	0.000618	0.0232	CcSEcCtD
Loperamide—Abdominal pain—Varenicline—nicotine dependence	0.000615	0.023	CcSEcCtD
Loperamide—CYP2C8—brain—nicotine dependence	0.000601	0.018	CbGeAlD
Loperamide—ABCB1—cardiovascular system—nicotine dependence	0.000587	0.0176	CbGeAlD
Loperamide—Hypersensitivity—Varenicline—nicotine dependence	0.000573	0.0215	CcSEcCtD
Loperamide—Asthenia—Varenicline—nicotine dependence	0.000558	0.0209	CcSEcCtD
Loperamide—Pruritus—Varenicline—nicotine dependence	0.000551	0.0206	CcSEcCtD
Loperamide—CYP2B6—brain—nicotine dependence	0.000539	0.0162	CbGeAlD
Loperamide—Diarrhoea—Varenicline—nicotine dependence	0.000532	0.0199	CcSEcCtD
Loperamide—CALM1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB3—nicotine dependence	0.000526	0.00437	CbGpPWpGaD
Loperamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000525	0.00436	CbGpPWpGaD
Loperamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000518	0.0043	CbGpPWpGaD
Loperamide—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000518	0.0043	CbGpPWpGaD
Loperamide—CALM3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA6—nicotine dependence	0.000516	0.00429	CbGpPWpGaD
Loperamide—Dizziness—Varenicline—nicotine dependence	0.000515	0.0193	CcSEcCtD
Loperamide—POMC—Signaling by GPCR—FGD1—nicotine dependence	0.000512	0.00425	CbGpPWpGaD
Loperamide—POMC—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000509	0.00423	CbGpPWpGaD
Loperamide—OPRD1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000505	0.00419	CbGpPWpGaD
Loperamide—CALM1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA6—nicotine dependence	0.000499	0.00415	CbGpPWpGaD
Loperamide—CALM2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA6—nicotine dependence	0.000499	0.00415	CbGpPWpGaD
Loperamide—Vomiting—Varenicline—nicotine dependence	0.000495	0.0185	CcSEcCtD
Loperamide—Rash—Varenicline—nicotine dependence	0.000491	0.0184	CcSEcCtD
Loperamide—Dermatitis—Varenicline—nicotine dependence	0.00049	0.0184	CcSEcCtD
Loperamide—Headache—Varenicline—nicotine dependence	0.000487	0.0183	CcSEcCtD
Loperamide—Levomethadyl Acetate—OPRM1—nicotine dependence	0.000464	0.05	CrCbGaD
Loperamide—Nausea—Varenicline—nicotine dependence	0.000462	0.0173	CcSEcCtD
Loperamide—ABCB1—midbrain—nicotine dependence	0.000459	0.0138	CbGeAlD
Loperamide—OPRK1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000443	0.00368	CbGpPWpGaD
Loperamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000425	0.00353	CbGpPWpGaD
Loperamide—OPRD1—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.000417	0.00346	CbGpPWpGaD
Loperamide—CALM3—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.000409	0.0034	CbGpPWpGaD
Loperamide—Dextropropoxyphene—OPRM1—nicotine dependence	0.000401	0.0432	CrCbGaD
Loperamide—CYP2D6—brain—nicotine dependence	0.000401	0.012	CbGeAlD
Loperamide—Fentanyl—OPRM1—nicotine dependence	0.000397	0.0427	CrCbGaD
Loperamide—CALM1—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.000396	0.00329	CbGpPWpGaD
Loperamide—CALM2—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.000396	0.00329	CbGpPWpGaD
Loperamide—CALM3—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.000388	0.00322	CbGpPWpGaD
Loperamide—POMC—GPCR ligand binding—DRD2—nicotine dependence	0.000388	0.00322	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—TAS2R16—nicotine dependence	0.000386	0.0032	CbGpPWpGaD
Loperamide—CALM3—Opioid Signalling—OPRM1—nicotine dependence	0.000378	0.00314	CbGpPWpGaD
Loperamide—CALM1—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.000375	0.00312	CbGpPWpGaD
Loperamide—CALM2—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.000375	0.00312	CbGpPWpGaD
Loperamide—OPRM1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000374	0.00311	CbGpPWpGaD
Loperamide—CALM3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA4—nicotine dependence	0.000373	0.0031	CbGpPWpGaD
Loperamide—CALM2—Opioid Signalling—OPRM1—nicotine dependence	0.000366	0.00304	CbGpPWpGaD
Loperamide—CALM1—Opioid Signalling—OPRM1—nicotine dependence	0.000366	0.00304	CbGpPWpGaD
Loperamide—OPRK1—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.000365	0.00303	CbGpPWpGaD
Loperamide—CALM2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA4—nicotine dependence	0.000361	0.003	CbGpPWpGaD
Loperamide—CALM1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA4—nicotine dependence	0.000361	0.003	CbGpPWpGaD
Loperamide—CALM3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB4—nicotine dependence	0.000358	0.00297	CbGpPWpGaD
Loperamide—CALM3—ErbB1 downstream signaling—WASF2—nicotine dependence	0.000356	0.00296	CbGpPWpGaD
Loperamide—OPRD1—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000351	0.00292	CbGpPWpGaD
Loperamide—CALM3—VEGFA-VEGFR2 Pathway—WASF2—nicotine dependence	0.000351	0.00291	CbGpPWpGaD
Loperamide—CALM2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB4—nicotine dependence	0.000346	0.00287	CbGpPWpGaD
Loperamide—CALM1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB4—nicotine dependence	0.000346	0.00287	CbGpPWpGaD
Loperamide—CYP2B6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000345	0.00286	CbGpPWpGaD
Loperamide—CALM2—ErbB1 downstream signaling—WASF2—nicotine dependence	0.000344	0.00286	CbGpPWpGaD
Loperamide—CALM1—ErbB1 downstream signaling—WASF2—nicotine dependence	0.000344	0.00286	CbGpPWpGaD
Loperamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000343	0.00285	CbGpPWpGaD
Loperamide—CALM2—VEGFA-VEGFR2 Pathway—WASF2—nicotine dependence	0.000339	0.00282	CbGpPWpGaD
Loperamide—CALM1—VEGFA-VEGFR2 Pathway—WASF2—nicotine dependence	0.000339	0.00282	CbGpPWpGaD
Loperamide—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000339	0.00281	CbGpPWpGaD
Loperamide—CALM3—VEGFA-VEGFR2 Pathway—WASF1—nicotine dependence	0.000336	0.00279	CbGpPWpGaD
Loperamide—CALM3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—nicotine dependence	0.000332	0.00276	CbGpPWpGaD
Loperamide—CALM3—Signaling by VEGF—WASF2—nicotine dependence	0.000331	0.00275	CbGpPWpGaD
Loperamide—OPRD1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000326	0.00271	CbGpPWpGaD
Loperamide—CYP2B6—Biological oxidations—CYP2A7—nicotine dependence	0.000325	0.0027	CbGpPWpGaD
Loperamide—CALM2—VEGFA-VEGFR2 Pathway—WASF1—nicotine dependence	0.000325	0.0027	CbGpPWpGaD
Loperamide—CALM1—VEGFA-VEGFR2 Pathway—WASF1—nicotine dependence	0.000325	0.0027	CbGpPWpGaD
Loperamide—CALM2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—nicotine dependence	0.000322	0.00267	CbGpPWpGaD
Loperamide—CALM1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—nicotine dependence	0.000322	0.00267	CbGpPWpGaD
Loperamide—CYP2B6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000321	0.00266	CbGpPWpGaD
Loperamide—CALM1—Signaling by VEGF—WASF2—nicotine dependence	0.00032	0.00266	CbGpPWpGaD
Loperamide—CALM2—Signaling by VEGF—WASF2—nicotine dependence	0.00032	0.00266	CbGpPWpGaD
Loperamide—CALM3—Signaling by VEGF—WASF1—nicotine dependence	0.000317	0.00263	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—CHRNB3—nicotine dependence	0.000313	0.0026	CbGpPWpGaD
Loperamide—OPRK1—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000308	0.00256	CbGpPWpGaD
Loperamide—CALM2—Signaling by VEGF—WASF1—nicotine dependence	0.000307	0.00255	CbGpPWpGaD
Loperamide—CALM1—Signaling by VEGF—WASF1—nicotine dependence	0.000307	0.00255	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—CHRNB3—nicotine dependence	0.000303	0.00252	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—CHRNB3—nicotine dependence	0.000303	0.00252	CbGpPWpGaD
Loperamide—POMC—GPCR downstream signaling—OPRM1—nicotine dependence	0.000303	0.00252	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—FGD1—nicotine dependence	0.000303	0.00251	CbGpPWpGaD
Loperamide—POMC—Metabolism—CYP2A7—nicotine dependence	0.000297	0.00247	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—CHRNA6—nicotine dependence	0.000297	0.00247	CbGpPWpGaD
Loperamide—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000292	0.00242	CbGpPWpGaD
Loperamide—ABCB1—brain—nicotine dependence	0.000288	0.00864	CbGeAlD
Loperamide—CALM2—Neuronal System—CHRNA6—nicotine dependence	0.000287	0.00239	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—CHRNA6—nicotine dependence	0.000287	0.00239	CbGpPWpGaD
Loperamide—OPRK1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000286	0.00238	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000285	0.00237	CbGpPWpGaD
Loperamide—CALM3—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.00028	0.00233	CbGpPWpGaD
Loperamide—OPRD1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000279	0.00232	CbGpPWpGaD
Loperamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000278	0.00231	CbGpPWpGaD
Loperamide—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.000275	0.00229	CbGpPWpGaD
Loperamide—POMC—Signaling by GPCR—OPRM1—nicotine dependence	0.000275	0.00229	CbGpPWpGaD
Loperamide—Methadone—OPRM1—nicotine dependence	0.000272	0.0293	CrCbGaD
Loperamide—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000271	0.00225	CbGpPWpGaD
Loperamide—CALM2—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.000271	0.00225	CbGpPWpGaD
Loperamide—CALM1—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.000271	0.00225	CbGpPWpGaD
Loperamide—CALM3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—nicotine dependence	0.000271	0.00225	CbGpPWpGaD
Loperamide—CALM3—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.000269	0.00223	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—AKR1B10—nicotine dependence	0.000267	0.00222	CbGpPWpGaD
Loperamide—CALM1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—nicotine dependence	0.000262	0.00218	CbGpPWpGaD
Loperamide—CALM2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—nicotine dependence	0.000262	0.00218	CbGpPWpGaD
Loperamide—CALM2—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.00026	0.00216	CbGpPWpGaD
Loperamide—CALM1—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.00026	0.00216	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000259	0.00215	CbGpPWpGaD
Loperamide—CACNA1A—Metabolism—CYP2A7—nicotine dependence	0.000257	0.00213	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—FGD1—nicotine dependence	0.000257	0.00213	CbGpPWpGaD
Loperamide—OPRD1—G alpha (i) signalling events—DRD2—nicotine dependence	0.000254	0.00211	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00025	0.00208	CbGpPWpGaD
Loperamide—CALM3—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.00025	0.00208	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—FGD1—nicotine dependence	0.000248	0.00206	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—FGD1—nicotine dependence	0.000248	0.00206	CbGpPWpGaD
Loperamide—OPRK1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000245	0.00204	CbGpPWpGaD
Loperamide—CALM1—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.000242	0.00201	CbGpPWpGaD
Loperamide—CALM2—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.000242	0.00201	CbGpPWpGaD
Loperamide—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00024	0.00199	CbGpPWpGaD
Loperamide—CALM3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB2—nicotine dependence	0.000239	0.00198	CbGpPWpGaD
Loperamide—OPRD1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000236	0.00196	CbGpPWpGaD
Loperamide—CALM2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB2—nicotine dependence	0.000231	0.00192	CbGpPWpGaD
Loperamide—CALM1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB2—nicotine dependence	0.000231	0.00192	CbGpPWpGaD
Loperamide—Haloperidol—DRD2—nicotine dependence	0.000229	0.0247	CrCbGaD
Loperamide—OPRK1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000227	0.00189	CbGpPWpGaD
Loperamide—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000226	0.00188	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—FGD1—nicotine dependence	0.000224	0.00186	CbGpPWpGaD
Loperamide—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000223	0.00185	CbGpPWpGaD
Loperamide—OPRK1—G alpha (i) signalling events—DRD2—nicotine dependence	0.000223	0.00185	CbGpPWpGaD
Loperamide—POMC—GPCR downstream signaling—DRD2—nicotine dependence	0.000219	0.00182	CbGpPWpGaD
Loperamide—CALM3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA4—nicotine dependence	0.000217	0.0018	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—GABRA4—nicotine dependence	0.000215	0.00178	CbGpPWpGaD
Loperamide—OPRD1—GPCR ligand binding—OPRM1—nicotine dependence	0.000213	0.00177	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000211	0.00176	CbGpPWpGaD
Loperamide—CALM2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA4—nicotine dependence	0.00021	0.00174	CbGpPWpGaD
Loperamide—CALM1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA4—nicotine dependence	0.00021	0.00174	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—GABRA4—nicotine dependence	0.000208	0.00173	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—GABRA4—nicotine dependence	0.000208	0.00173	CbGpPWpGaD
Loperamide—OPRK1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000207	0.00172	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—CHRNB4—nicotine dependence	0.000206	0.00171	CbGpPWpGaD
Loperamide—CALM3—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.000204	0.00169	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—FGD1—nicotine dependence	0.000203	0.00169	CbGpPWpGaD
Loperamide—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000202	0.00168	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—CHRNB4—nicotine dependence	0.000199	0.00165	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—CHRNB4—nicotine dependence	0.000199	0.00165	CbGpPWpGaD
Loperamide—POMC—Signaling by GPCR—DRD2—nicotine dependence	0.000199	0.00165	CbGpPWpGaD
Loperamide—CALM1—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.000197	0.00164	CbGpPWpGaD
Loperamide—CALM2—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.000197	0.00164	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—FGD1—nicotine dependence	0.000196	0.00163	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000192	0.00159	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—CHRNA5—nicotine dependence	0.000192	0.00159	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—WASF2—nicotine dependence	0.000188	0.00156	CbGpPWpGaD
Loperamide—OPRM1—G alpha (i) signalling events—DRD2—nicotine dependence	0.000188	0.00156	CbGpPWpGaD
Loperamide—OPRK1—GPCR ligand binding—OPRM1—nicotine dependence	0.000187	0.00155	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—CHRNA5—nicotine dependence	0.000185	0.00154	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—CHRNA5—nicotine dependence	0.000185	0.00154	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—WASF1—nicotine dependence	0.000181	0.0015	CbGpPWpGaD
Loperamide—CALM3—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.000179	0.00149	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—FGD1—nicotine dependence	0.000178	0.00148	CbGpPWpGaD
Loperamide—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000177	0.00147	CbGpPWpGaD
Loperamide—OPRM1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000175	0.00145	CbGpPWpGaD
Loperamide—CALM1—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.000174	0.00144	CbGpPWpGaD
Loperamide—CALM2—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.000174	0.00144	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—FGD1—nicotine dependence	0.000166	0.00138	CbGpPWpGaD
Loperamide—CALM3—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.000163	0.00135	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—OPRM1—nicotine dependence	0.000163	0.00135	CbGpPWpGaD
Loperamide—CALM2—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.000158	0.00131	CbGpPWpGaD
Loperamide—CALM1—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.000158	0.00131	CbGpPWpGaD
Loperamide—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000157	0.0013	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—CHRNA3—nicotine dependence	0.000156	0.0013	CbGpPWpGaD
Loperamide—OPRD1—GPCR ligand binding—DRD2—nicotine dependence	0.000154	0.00128	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TAS2R16—nicotine dependence	0.000153	0.00127	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—CHRNA3—nicotine dependence	0.000151	0.00125	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—CHRNA3—nicotine dependence	0.000151	0.00125	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—FGD1—nicotine dependence	0.000151	0.00125	CbGpPWpGaD
Loperamide—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00015	0.00124	CbGpPWpGaD
Loperamide—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000148	0.00123	CbGpPWpGaD
Loperamide—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000146	0.00121	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—CHRNB2—nicotine dependence	0.000137	0.00114	CbGpPWpGaD
Loperamide—OPRK1—GPCR ligand binding—DRD2—nicotine dependence	0.000135	0.00112	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TAS2R16—nicotine dependence	0.000134	0.00111	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—CHRNB2—nicotine dependence	0.000133	0.0011	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—CHRNB2—nicotine dependence	0.000133	0.0011	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—CHRNA4—nicotine dependence	0.000125	0.00104	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—CHRNA4—nicotine dependence	0.000121	0.001	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—CHRNA4—nicotine dependence	0.000121	0.001	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—OPRM1—nicotine dependence	0.00012	0.000999	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—FGD1—nicotine dependence	0.00012	0.000997	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—TAS2R16—nicotine dependence	0.000119	0.000987	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—DRD2—nicotine dependence	0.000118	0.000976	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—TAS2R16—nicotine dependence	0.000115	0.000955	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000115	0.000955	CbGpPWpGaD
Loperamide—OPRM1—GPCR ligand binding—DRD2—nicotine dependence	0.000114	0.000947	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TAS2R16—nicotine dependence	0.000113	0.000942	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—OPRM1—nicotine dependence	0.000109	0.000907	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—AKR1B10—nicotine dependence	0.000106	0.000881	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—OPRM1—nicotine dependence	0.000105	0.000876	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—FGD1—nicotine dependence	0.000105	0.000875	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—OPRM1—nicotine dependence	9.58e-05	0.000795	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—FGD1—nicotine dependence	9.33e-05	0.000775	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—AKR1B10—nicotine dependence	9.3e-05	0.000773	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—WASF2—nicotine dependence	9.1e-05	0.000756	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—FGD1—nicotine dependence	9.02e-05	0.000749	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—FGD1—nicotine dependence	9.02e-05	0.000749	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—FGD1—nicotine dependence	8.9e-05	0.000739	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—WASF2—nicotine dependence	8.81e-05	0.000732	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—WASF2—nicotine dependence	8.81e-05	0.000732	CbGpPWpGaD
Loperamide—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	8.75e-05	0.000727	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—WASF1—nicotine dependence	8.73e-05	0.000725	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—DRD2—nicotine dependence	8.7e-05	0.000722	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—WASF1—nicotine dependence	8.44e-05	0.000701	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—WASF1—nicotine dependence	8.44e-05	0.000701	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—DRD2—nicotine dependence	7.9e-05	0.000656	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—AKR1B10—nicotine dependence	7.86e-05	0.000653	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—DRD2—nicotine dependence	7.62e-05	0.000633	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—WASF2—nicotine dependence	7.47e-05	0.000621	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—WASF1—nicotine dependence	7.17e-05	0.000595	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TAS2R16—nicotine dependence	7.02e-05	0.000583	CbGpPWpGaD
Loperamide—CALM3—Disease—AKR1B10—nicotine dependence	6.95e-05	0.000577	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—DRD2—nicotine dependence	6.92e-05	0.000575	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TAS2R16—nicotine dependence	6.79e-05	0.000564	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TAS2R16—nicotine dependence	6.79e-05	0.000564	CbGpPWpGaD
Loperamide—CALM1—Disease—AKR1B10—nicotine dependence	6.72e-05	0.000558	CbGpPWpGaD
Loperamide—CALM2—Disease—AKR1B10—nicotine dependence	6.72e-05	0.000558	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—WASF2—nicotine dependence	6.55e-05	0.000544	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—OPRM1—nicotine dependence	6.45e-05	0.000536	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—DRD2—nicotine dependence	6.44e-05	0.000535	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—WASF1—nicotine dependence	6.28e-05	0.000522	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—DRD2—nicotine dependence	5.85e-05	0.000486	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—OPRM1—nicotine dependence	5.66e-05	0.00047	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—CYP2A7—nicotine dependence	5.56e-05	0.000462	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—WASF2—nicotine dependence	5.54e-05	0.00046	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—FGD1—nicotine dependence	5.51e-05	0.000458	CbGpPWpGaD
Loperamide—CALM3—Metabolism—CYP2A7—nicotine dependence	5.41e-05	0.000449	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—FGD1—nicotine dependence	5.33e-05	0.000443	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—FGD1—nicotine dependence	5.33e-05	0.000443	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—WASF1—nicotine dependence	5.31e-05	0.000441	CbGpPWpGaD
Loperamide—CALM3—Immune System—WASF2—nicotine dependence	5.3e-05	0.00044	CbGpPWpGaD
Loperamide—CALM2—Metabolism—CYP2A7—nicotine dependence	5.23e-05	0.000435	CbGpPWpGaD
Loperamide—CALM1—Metabolism—CYP2A7—nicotine dependence	5.23e-05	0.000435	CbGpPWpGaD
Loperamide—CALM2—Immune System—WASF2—nicotine dependence	5.13e-05	0.000426	CbGpPWpGaD
Loperamide—CALM1—Immune System—WASF2—nicotine dependence	5.13e-05	0.000426	CbGpPWpGaD
Loperamide—CALM3—Immune System—WASF1—nicotine dependence	5.08e-05	0.000422	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—OPRM1—nicotine dependence	5.01e-05	0.000416	CbGpPWpGaD
Loperamide—CALM1—Immune System—WASF1—nicotine dependence	4.92e-05	0.000408	CbGpPWpGaD
Loperamide—CALM2—Immune System—WASF1—nicotine dependence	4.92e-05	0.000408	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—AKR1B10—nicotine dependence	4.87e-05	0.000404	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—OPRM1—nicotine dependence	4.85e-05	0.000403	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—OPRM1—nicotine dependence	4.85e-05	0.000403	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—AKR1B10—nicotine dependence	4.71e-05	0.000391	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—AKR1B10—nicotine dependence	4.71e-05	0.000391	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—CYP2A7—nicotine dependence	4.71e-05	0.000391	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—DRD2—nicotine dependence	4.66e-05	0.000387	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CYP2A7—nicotine dependence	4.1e-05	0.000341	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—DRD2—nicotine dependence	4.09e-05	0.00034	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CYP2A7—nicotine dependence	3.86e-05	0.000321	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—DRD2—nicotine dependence	3.62e-05	0.000301	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—DRD2—nicotine dependence	3.5e-05	0.000291	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—DRD2—nicotine dependence	3.5e-05	0.000291	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—DRD2—nicotine dependence	3.46e-05	0.000287	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—WASF2—nicotine dependence	3.43e-05	0.000285	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—WASF2—nicotine dependence	3.32e-05	0.000275	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—WASF2—nicotine dependence	3.32e-05	0.000275	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—WASF1—nicotine dependence	3.29e-05	0.000273	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—WASF1—nicotine dependence	3.18e-05	0.000264	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—WASF1—nicotine dependence	3.18e-05	0.000264	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—OPRM1—nicotine dependence	2.96e-05	0.000246	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—OPRM1—nicotine dependence	2.86e-05	0.000238	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—OPRM1—nicotine dependence	2.86e-05	0.000238	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CYP2A7—nicotine dependence	2.53e-05	0.00021	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—DRD2—nicotine dependence	2.14e-05	0.000178	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—DRD2—nicotine dependence	2.07e-05	0.000172	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—DRD2—nicotine dependence	2.07e-05	0.000172	CbGpPWpGaD
